EPEMED, the European PErsonalised MEdicine Diagnostics association announces the appointment of its founding board of directors
EPEMED, a membership association formed in August 2009 as a not-for- profit organisation, will provide a platform for harmonisation in the development and implementation of value-based diagnostics across Europe, to make personalised medicine a reality. Personalised Medicine, the use of a person’s clinical, genetic, genomic and environmental information to more precisely and accurately select a medication and its dose for each individual patient, will both improve care and lower costs.
EPEMED has appointed experts in the field of personalised medicine and molecular diagnostics as its founding board of directors:
- Alain Huriez, M.D., Chairman, CEO TcLand Expression
- Mara Aspinall, President & CEO, On-Q-ity, ex. president, Genzyme Genetics
- Vincent Fert, President & CEO Ipsogen
- Werner Kroll, Ph.D., Head Diagnostics Research and Innovation Novartis Molecular Diagnostics
- Iain D. Miller, Ph.D., Senior Director, Oncology Strategy and Theranostics, bioMerieux
- Herman Spolders, BVBA, CEO Oncomethylome Sciences
- Patrick F. Terry, founder Genomic Health & PMC, CEO Technic Solutions
Organizations
Other news from the department people
Get the analytics and lab tech industry in your inbox
From now on, don't miss a thing: Our newsletter for analytics and lab technology brings you up to date every Tuesday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.